Germany Pharmaceuticals and Healthcare Report Q3 2011
Business Monitor International, June 2011, Pages: 108
The Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Germany's pharmaceuticals and healthcare industry.
The Analysts View:
Despite the threat of austerity measures, the government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the patent cliff, this report expects Germany to remain attractive to innovative drugmakers. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent – factors the analysts believes will continue to bring in substantial income for companies operating in the country.
Headline Expenditure Projections:
- Pharmaceuticals: EUR38.35bn (US$50.87bn) in 2010 to EUR38.85bn (US$55.57bn) in 2011; +1.3% growth in local currency terms and +9.2% in US dollar terms. The forecast has been revised up moderately from Q111 due to macroeconomic factors.
- Healthcare: EUR269.99bn (US$358.14bn) in 2010 to EUR274.99bn (US$393.24bn) in 2011; 1.9% growth in local currency terms and 9.8% in US dollar terms. The forecast has been revised up moderately from Q111 due to macroeconomic factors.
- Medical devices: EUR13.00bn (US$17.24bn) in 2010 to EUR13.40bn (US$19.16bn) in 2011; 3.1% growth in local currency terms and 11.1% in US dollar terms. The forecast has has been revised down moderately from Q111 due to analyst intervention.
Business Environment Rating: While Germany is ranked third in the Pharmaceutical and Healthcare Business Environment Ratings (BERs) for Q311, the country will remain attractive to drugmakers. In 2010, Germany's drug market was the fourth largest globally after the US, Japan and China. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent.
Key Trends & Developments:
- In November 2010, the Bundestag finalised the Reorganisation of the Pharmaceutical Market (Arzneimittelmarkt-Neuordnungsgesetz; Amnog) bill, which requires drug companies and health insurers to negotiate the prices of new drugs based on cost-effectiveness criteria which came into effect in January 2011.
- In May 2011, Biocon announced that it was selling its entire 78% stake in its German unit AxiCorp to minority shareholders for EUR40mn (US$58.2mn). AxiCorp was the licensee for Biocon's insulin and Glargine products in Germany and had the sole responsibility for commercialising them.
The Analysts Economic View:
Leading indicators throughout the first quarter of 2011 reaffirm a constructive outlook on the German economy, underpinning the above-consensus 3.0% real GDP growth forecast for 2011. 'Current situation' business confidence indices across the board have continued to head higher in recent months, with the Ifo Business Climate index hitting an all-time high of 111.3 in February, and staying near this level (111.1) in March. The 'business situation' component of the index, which reflects the assessment of Germany's current economic conditions by some 7,000 respondents in construction, manufacturing, wholesale and retail trade, hit a new high of 115.8 in March, taking out the previous peak of 115.4 hit in December 2006.
The Analysts Political View:
Germany's centre-right government continues to pick up the pieces after a string of election defeats in key states, clouding the country's policy direction. The government has already backtracked on its controversial nuclear energy policy and the report does not rule out further policy changes. Although the reshuffle at the junior Free Democrat coalition partner and the rise of the Green party in German politics further cloud the policy environment, this report notes that the opposition will now have to prove itself as a viable alternative to Chancellor Angela Merkel ahead of the 2013 federal election.
Executive Summary
SWOT Analysis
- Germany Pharmaceuticals And Healthcare Industry SWOT
- Germany Political SWOT
- Germany Economic SWOT
- Germany Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Ratings For Q311
- Rewards
- Risks
Germany – Market Summary
Regulatory Regime
- Intellectual Property (IP) Developments
- Recent IP Developments
- Pricing Regime
- Table: Price Build-Up in the German Pharmaceutical Market
- Recent Pricing Developments
- Reimbursement Regime
- Recent Reimbursement Developments
- Parallel Imports
Industry Developments
- Epidemiology
- Communicable Disease
- Healthcare Sector
- Healthcare Sector Reforms
- Krankenkassen
- Research & Development
- Biotechnology Sector
- Medical Devices Industry
- Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Market Forecast, 2007-2015
- Key Growth Factors – Industry
- Table: Germany Healthcare Expenditure Forecast, 2007-2015
- Key Growth Factors – Macroeconomic
- Table: Germany – Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Market Forecast, 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Forecast, 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Market Forecast, 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Market Forecast, 2007-2015
- Medical Device Market Forecast
- Table: Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Trade Forecast, 2007-2015 (US$mn)
- Other Healthcare Data and Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Table: Leading Local Pharmaceutical Companies According To Market Capitalisation
- Recent Company Developments
- Wholesale Sector
- Recent Wholesale Sector Developments
- Retail Sector
- Recent Retail Sector Developments
Company Profiles
- Domestic Manufacturer Profiles
- Bayer HealthCare
- Boehringer Ingelheim
- Stada Arzneimittel
- Grünenthal
- Merck KGaA
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
Country Snapshot: Germany Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages
Glossary
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
